Zobrazeno 1 - 10
of 38
pro vyhledávání: '"John Nicoll"'
Autor:
John Nicoll
Publikováno v:
Australian Film Theory and Criticism ISBN: 9781783208388
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68c77a4697ec8769f0700aa94a6bdfc9
https://doi.org/10.2307/j.ctv36xw41t.22
https://doi.org/10.2307/j.ctv36xw41t.22
Autor:
Meenal Chalukya, Charles L. Sawyers, P. Nagesh Rao, John Nicoll, Neil P. Shah, Elizabeth Spiteri, Ronald Paquette, David Elashoff, Gouri Nanjangud
Publikováno v:
Cancer Genetics. 204:392-397
Clinical variables associated with ecotropic viral integration site 1 (EVI1) translocations were evaluated in 42 consecutive chronic myeloid leukemia (CML) patients in myeloid blast crisis (MBC). Translocations were confirmed with fluorescence in sit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dbe2b0042fd62b9369e412c500dade7
https://doi.org/10.1016/j.cancergen.2011.06.002
https://doi.org/10.1016/j.cancergen.2011.06.002
Autor:
Claude Nicaise, Charles L. Sawyers, Eric Bleickardt, Neil P. Shah, Minna D. Balbas, Christopher Weier, John Nicoll, Corynn Kasap
Publikováno v:
Cancer Cell. 14(6):485-493
SummaryThe BCR-ABL inhibitor dasatinib achieves clinical remissions in chronic myeloid leukemia (CML) patients using a dosing schedule that achieves potent but transient BCR-ABL inhibition. In vitro, transient potent BCR-ABL inhibition with either da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10b591264f16a1939e3087dd2a0d27e2
Autor:
MICHAEL JOHN NICOLL
Publikováno v:
Ibis. 68:189-192
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e852df5659d213510185fefee6f1c45
https://doi.org/10.1111/j.1474-919x.1926.tb07564.x
https://doi.org/10.1111/j.1474-919x.1926.tb07564.x
Autor:
Charles L. Sawyers, John Nicoll, Neil P. Shah, Timothy P. Hughes, Susan Branford, Brian J. Skaggs, Ronald Paquette
Publikováno v:
Journal of Clinical Investigation. 117:2562-2569
Molecularly targeted kinase inhibitor cancer therapies are currently administered sequentially rather than simultaneously. We addressed the potential long-term impact of this strategy in patients with chronic myelogenous leukemia (CML), which is driv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0edd3d5f6db02d4ce810e3728b342bf
https://doi.org/10.1172/jci30890
https://doi.org/10.1172/jci30890
Autor:
Neil P. Shah, Bhushan Nagar, Ronald Paquette, John Nicoll, Mercedes E. Gorre, Charles L. Sawyers, John Kuriyan
Publikováno v:
Cancer Cell. 2(2):117-125
Through sequencing analysis of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc3056cb8f75213a770d465506ff27b3
Autor:
Charles L. Sawyers, Mercedes E. Gorre, Neil P. Shah, Richard A. Van Etten, John Nicoll, Sergei Roumiantsev, Bradley B. Brasher
Publikováno v:
Proceedings of the National Academy of Sciences. 99:10700-10705
The Abl tyrosine kinase inhibitor STI-571 is effective therapy for stable phase chronic myeloid leukemia (CML) patients, but the majority of CML blast-crisis patients that respond to STI-571 relapse because of reactivation of Bcr-Abl signaling. Mutat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::884cda474980b83001ea48ed6b2dc91f
https://doi.org/10.1073/pnas.162140299
https://doi.org/10.1073/pnas.162140299
Autor:
Christina Van Loy, Jonathan P. Katz, Antonio Sanchez, Anjana Soundararajan, Mitchell E. Gross, Zhao Xu, Erika Feierstein, Daniel Ruderman, Katherin Patsch, Naim Matasci, David B. Agus, John Nicoll
Publikováno v:
Cancer Research. 77:3934-3934
Survival rates for patients with muscle-invasive bladder cancer have not improved in the past 20 years, and new therapies are imperative. Intratumor heterogeneity can complicate molecular profiling attempts to optimize therapy for cancers harboring s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5cf407af170e40cb7b2b3fb23b52b73
https://doi.org/10.1158/1538-7445.am2017-3934
https://doi.org/10.1158/1538-7445.am2017-3934
Autor:
David M. H. Wu, Yujun Zhang, Nereida A. Parada, Hardy Kornfeld, John Nicoll, David M. Center, William W. Cruikshank
Publikováno v:
The Journal of Immunology. 162:1287-1293
IL-16 is synthesized as a precursor molecule of 68 kDa (pro-IL-16) that is processed by caspase-3, a member of the IL-1 converting enzyme (ICE) family. This cleavage results in a 13-kDa carboxy terminal peptide, which constitutes the bioactive secret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31e5e8aebd32a64f9aa4e05f80f158c0
https://doi.org/10.4049/jimmunol.162.3.1287
https://doi.org/10.4049/jimmunol.162.3.1287
Autor:
Bartlomiej P Przychodzen, John Nicoll, Anna M. Jankowska, Jaroslaw P. Maciejewski, Michael A. McDevitt, Harish Siddaiah, Ronald Paquette, Simon Dujardin, Christine L. O'Keefe, Hadrian Szpurka, Courtney Prince, Eric D. Hsi, Hideki Makishima, Anjali S. Advani, Mohammed Shaik, Heather Cazzolli
Publikováno v:
Blood. 117(21)
Progression of chronic myelogenous leukemia (CML) to accelerated (AP) and blast phase (BP) is because of secondary molecular events, as well as additional cytogenetic abnormalities. On the basis of the detection of JAK2, CBL, CBLB, TET2, ASXL1, and I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e6e7244c669923fc1048361a09b7980
https://pubmed.ncbi.nlm.nih.gov/21940831
https://pubmed.ncbi.nlm.nih.gov/21940831